Amp Volatility Score
Catalyst Info & Data Links
NCT04283461: Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19)
May 7, 2020 Progress on novel coronavirus vaccine (mRNA-1273) includes FDA clearance to proceed with Phase 2 study/Finalizing protocol for Phase 3 study of mRNA-1273, expected to begin in early summer of 2020
May 17, 2020: Phase 1 Interim Safety & Immunogenicity Data
Feldman, R. A., Fuhr, R., Smolenov, I., Ribeiro, A. M., Panther, L., Watson, M., ... & Laska, M. E. (2019). mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials. Vaccine, 37(25), 3326-3334.
John, S., Yuzhakov, O., Woods, A., Deterling, J., Hassett, K., Shaw, C. A., & Ciaramella, G. (2018). Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity. Vaccine, 36(12), 1689-1699.
Bahl, K., Senn, J. J., Yuzhakov, O., Bulychev, A., Brito, L. A., Hassett, K. J., ... & Ribeiro, A. M. (2017). Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses. Molecular Therapy, 25(6), 1316-1327.
HC updated 5/21/20